Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
The US private equity firm Blackstone Group, which will acquire Takeda Pharmaceutical’s consumer healthcare subsidiary, will invest in the growth of the OTC company with the goal of taking it public in five to 10 years, the investment firm’s Japan…
To read the full story
Related Article
- Alinamin Invites New President from Non-Pharma Sector
June 22, 2022
- Takeda’s OTC Unit to Be Renamed Alinamin with New Chief from Blackstone
March 22, 2021
- Takeda to Sell Japan OTC Biz to Blackstone, Weber Says It’s the Right Choice
August 25, 2020
- Takeda to Offload Japan OTC Biz to Blackstone for 242 Billion Yen
August 24, 2020
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
- Viatris Eyes Japan Filing This Year for IgAN Drug
July 1, 2026
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…